Mylan issued a voluntary withdrawal of calcium chloride intravenous infusion 10% w/v 10mL prefilled syringe due to difficulties in administration.
In April 2015, Mylan issued a voluntary market withdrawal of 14 lots of calcium chloride intravenous infusion 10% w/v, packaged in 10 mL prefilled syringes due to difficulties in administration. The company issued a second notification of the market withdrawal in June 2015. FDA reported that some units of this drug could still be on the market and has advised healthcare professionals to examine their inventory and crash boxes. Affected lots should be quarantined and distribution discontinued.
The product was withdrawn as a precautionary measure following complaints of difficulties administering the drug as a result of incompatibility between the syringe and certain needleless adaptors. Calcium chloride intravenous infusion 10% w/v is used in emergency situations and any difficulty in administering the product has the potential risk of hindering or delaying the administration of the life-saving medication.
Calcium chloride intravenous infusion 10% w/v is used as part of the resuscitation procedure following a cardiac arrest and for the treatment of low calcium levels. It is also used for arrhythmias associated with hypocalcaemia, hyperkalaemia or hypomagnesaemia.
The lots involved with this market withdrawal were distributed in the United States between March 19, 2014, and February 24, 2015. The calcium chloride product is packaged with an Agila and Amneal label. Amneal is a marketing partner with Agila for calcium chloride intravenous infusion 10%w/v, 10 mL prefilled syringes.
Source: FDA
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.